MA38144A1 - Compositions et procédés pour le traitement de protéinopathies - Google Patents

Compositions et procédés pour le traitement de protéinopathies

Info

Publication number
MA38144A1
MA38144A1 MA38144A MA38144A MA38144A1 MA 38144 A1 MA38144 A1 MA 38144A1 MA 38144 A MA38144 A MA 38144A MA 38144 A MA38144 A MA 38144A MA 38144 A1 MA38144 A1 MA 38144A1
Authority
MA
Morocco
Prior art keywords
methods
mammal
proteinopathies
compositions
treatment
Prior art date
Application number
MA38144A
Other languages
English (en)
French (fr)
Inventor
Sergio Pablo Sardi
Lamya Shihabuddin
Seng Cheng
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49578599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38144(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA38144A1 publication Critical patent/MA38144A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA38144A 2012-11-05 2013-11-04 Compositions et procédés pour le traitement de protéinopathies MA38144A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261722434P 2012-11-05 2012-11-05
PCT/US2013/068242 WO2014071282A1 (en) 2012-11-05 2013-11-04 Compositions and methods for treating proteinopathies

Publications (1)

Publication Number Publication Date
MA38144A1 true MA38144A1 (fr) 2018-08-31

Family

ID=49578599

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38144A MA38144A1 (fr) 2012-11-05 2013-11-04 Compositions et procédés pour le traitement de protéinopathies

Country Status (22)

Country Link
US (1) US20150284472A1 (cg-RX-API-DMAC7.html)
EP (1) EP2914281A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016503405A (cg-RX-API-DMAC7.html)
KR (1) KR20150079751A (cg-RX-API-DMAC7.html)
CN (1) CN104902923A (cg-RX-API-DMAC7.html)
AR (1) AR093355A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013337354A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015009746A2 (cg-RX-API-DMAC7.html)
CA (1) CA2889990A1 (cg-RX-API-DMAC7.html)
CL (1) CL2015001157A1 (cg-RX-API-DMAC7.html)
CR (1) CR20150216A (cg-RX-API-DMAC7.html)
EA (1) EA201590880A1 (cg-RX-API-DMAC7.html)
HK (1) HK1214521A1 (cg-RX-API-DMAC7.html)
IL (1) IL238416A0 (cg-RX-API-DMAC7.html)
MA (1) MA38144A1 (cg-RX-API-DMAC7.html)
MX (1) MX2015005722A (cg-RX-API-DMAC7.html)
PH (1) PH12015500879A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201502989XA (cg-RX-API-DMAC7.html)
TN (1) TN2015000171A1 (cg-RX-API-DMAC7.html)
TW (1) TW201427695A (cg-RX-API-DMAC7.html)
WO (1) WO2014071282A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201502618B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2385735T3 (es) 2008-06-26 2012-07-31 Orphazyme Aps Uso de Hsp70 como regulador de la actividad enzimática
HUE046235T2 (hu) 2010-11-30 2020-02-28 Orphazyme As A HSP70 intercelluláris aktivitásának növelésére alkalmazott módszerek
KR20250069686A (ko) 2014-09-15 2025-05-19 제브라 덴마크 에이/에스 아리모클로몰 제제
US10967073B2 (en) * 2015-05-07 2021-04-06 The Mclean Hospital Corporation Glucocerebrosidase gene therapy for Parkinson's disease
SG10202100652VA (en) * 2015-07-21 2021-03-30 Univ Jefferson Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
CN108780473B (zh) * 2016-01-21 2022-08-16 蛋白质动态解决方案有限公司 用于光谱数据分析的方法和系统
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
CN109069496A (zh) * 2016-04-29 2018-12-21 奥菲泽米有限公司 用于治疗葡糖脑苷脂酶相关疾病的arimoclomol
EP3264092A1 (en) * 2016-07-01 2018-01-03 Centogene AG Use of lyso-gb1 as druggable target
MX2019001421A (es) * 2016-08-03 2019-09-04 Univ South Florida Composiciones de reelina para el tratamiento de trastornos neurologicos.
AU2018346104B2 (en) * 2017-10-03 2023-07-27 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
KR20220010062A (ko) 2017-10-03 2022-01-25 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
KR102709597B1 (ko) * 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
US20210261981A1 (en) * 2017-10-23 2021-08-26 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative diseases
JP7522033B2 (ja) * 2017-10-26 2024-07-24 武田薬品工業株式会社 グルコセレブロシダーゼ及びイソファゴミンを含む製剤
US20210041461A1 (en) * 2018-03-14 2021-02-11 Yissum Research Developmen Company Of The Hebrew University Of Jerusalem Ltd Detection of phospho-serine 129 alpha-synuclein in blood cells as a biomarker for synucleinopathies
EP3953378A1 (en) * 2019-04-10 2022-02-16 Prevail Therapeutics, Inc. Gene therapies for lysosomal disorders
FI3953377T3 (fi) 2019-04-10 2025-11-26 Prevail Therapeutics Inc Geeniterapioita lysosomaalisiin sairauksiin
MX2021015810A (es) 2019-06-21 2022-08-15 Broad Inst Inc Agentes para revertir las proteinopatias toxicas.
TW202214864A (zh) 2020-08-06 2022-04-16 應用醫學研究基金會 用於藉基因療法治療諸如阿茲海默症之Ｔａｕ蛋白病變的病毒顆粒
CA3198606A1 (en) * 2020-10-14 2022-04-21 Denali Therapeutics Inc. Methods for treating and monitoring frontotemporal dementia
CA3202568A1 (en) 2020-11-19 2022-05-27 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof
CN112569354B (zh) * 2020-12-29 2022-06-10 四川大学华西医院 tau蛋白及其基因作为药物靶点在制备治疗糖尿病药物中的应用
EP4448763A1 (en) * 2021-12-17 2024-10-23 F. Hoffmann-La Roche AG Oligonucleotide gba agonists
CN118382697A (zh) * 2021-12-17 2024-07-23 豪夫迈·罗氏有限公司 能够增加葡糖脑苷脂酶表达的寡核苷酸

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0564531T3 (da) 1990-12-03 1998-09-28 Genentech Inc Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US7264963B1 (en) 1995-08-18 2007-09-04 Morphosys Ag Protein(poly)peptide libraries
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DE60044997D1 (de) 1999-07-02 2010-11-04 Morphosys Ag Erzeugung spezifischer bindungspartner die an von genomischen dns-fragmenten oder ests kodierten (poly)peptiden binden
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
CA2410828C (en) 2000-06-01 2012-01-24 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
AU2007260812B2 (en) * 2006-06-23 2012-08-16 Amicus Therapeutics, Inc. Method for the treatment of neurological disorders by enhancing the activity of beta-glucocerebrosidase
PL2154969T3 (pl) * 2007-05-16 2016-04-29 Brigham & Womens Hospital Inc Leczenie synukleinopatii
EP2723384B1 (en) 2011-06-22 2018-08-29 The General Hospital Corporation Treatment of proteinopathies
EP2831039A1 (en) 2012-03-28 2015-02-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Salicylic acid derivatives useful as glucocerebrosidase activators

Also Published As

Publication number Publication date
TN2015000171A1 (fr) 2016-10-03
PH12015500879A1 (en) 2015-06-29
AU2013337354A1 (en) 2015-05-21
MX2015005722A (es) 2016-01-12
WO2014071282A1 (en) 2014-05-08
CL2015001157A1 (es) 2015-10-16
ZA201502618B (en) 2016-01-27
BR112015009746A2 (pt) 2017-08-15
JP2016503405A (ja) 2016-02-04
US20150284472A1 (en) 2015-10-08
SG11201502989XA (en) 2015-05-28
AR093355A1 (es) 2015-06-03
HK1214521A1 (zh) 2016-07-29
EP2914281A1 (en) 2015-09-09
CN104902923A (zh) 2015-09-09
TW201427695A (zh) 2014-07-16
CR20150216A (es) 2015-05-29
IL238416A0 (en) 2015-06-30
KR20150079751A (ko) 2015-07-08
CA2889990A1 (en) 2014-05-08
EA201590880A1 (ru) 2015-09-30

Similar Documents

Publication Publication Date Title
MA38144A1 (fr) Compositions et procédés pour le traitement de protéinopathies
TN2019000099A1 (en) Anti-lag-3 antibodies and compositions
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
MA40306A1 (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
MA33743B1 (fr) Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur
MA33295B1 (fr) Nouvelle formulation de diclofénac
MA35873B1 (fr) Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations
MA43283B1 (fr) Composition pour le traitement du cancer
BR112014028017A2 (pt) composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror
MA38478A1 (fr) Anticorps anti-pac1 humains
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
NZ702087A (en) Pharmaceutical compositions and treatment of mastitis
WO2020072126A8 (en) Modulating ptpn2 to increase immune responses and perturbing gene expression in hematopoietic stem cell lineages
MA20150436A1 (fr) Préparation pharmaceutique
IN2014DN08199A (cg-RX-API-DMAC7.html)
EP3309555A3 (en) Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation
MX2018005352A (es) Metodos y composiciones para el tratamiento de amiloidosis.
MA34815B1 (fr) Compositions comprenant un inhibiteur de pi3k et un inhibiteur de mek et leur utilisation pour le traitement du cancer
FR2972330B1 (fr) Composition nutraceutique pour limiter l'absorption de lipides alimentaires et pour induire une perte de poids comprenant comme agent actif au moins un extrait de carotte.
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
WO2008073466A3 (en) Alpha b-crystallin as a therapy for inflammation
WO2019017677A3 (ko) 시트랄을 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물